MicroAlgo Reports GAAP EPS $2.12, Revenue $60.05M MicroAlgo reported GAAP EPS $2.12 and revenue $60.05M on Apr 2, 2026; investors should probe revenue mix, client concentration, and deferred revenue to assess earnings quality.

MicroAlgo Reports GAAP EPS $2.12, Revenue $60.05M: MicroAlgo reported GAAP EPS $2.12 and revenue $60.05M on Apr 2, 2026; investors should probe revenue mix, client concentration, and deferred revenue to assess… 👈 Read full analysis #MicroAlgo #EarningsReport #GAAPEPS #RevenueGrowth #Investing

iFabric Corp Q1 GAAP EPS -$0.01 iFabric reported GAAP EPS of -$0.01 on Mar 31, 2026 (Seeking Alpha); the one-cent loss requires follow-up on cash flow and accounting drivers.

iFabric Corp Q1 GAAP EPS -$0.01: iFabric reported GAAP EPS of -$0.01 on Mar 31, 2026 (Seeking Alpha); the one-cent loss requires follow-up on cash flow and accounting drivers. 👈 Read full analysis #iFabric #GAAPEPS #EarningsReport #FinancialResults #SmallCapStocks

RenovoRx Reports Q1 GAAP EPS -$0.32, Revenue $1.12M RenovoRx reported GAAP EPS -$0.32 and revenue $1.12M for Q1 2026, missing consensus by $0.18M (≈13.8%) on Mar 30, 2026 (Seeking Alpha).

RenovoRx Reports Q1 GAAP EPS -$0.32, Revenue $1.12M: RenovoRx reported GAAP EPS -$0.32 and revenue $1.12M for Q1 2026, missing consensus by $0.18M (≈13.8%) on Mar 30, 2026 (Seeking Alpha). 👈 Read full analysis #RenovoRx #EarningsReport #GAAPEPS #FinanceNews #InvestmentInsights

Electra Battery Materials Posts GAAP EPS of -C$4.16 Electra reported GAAP EPS of -C$4.16 on Mar 30, 2026 (Source: Seeking Alpha). This large loss heightens liquidity and execution scrutiny amid volatile battery-material prices (~60–70% down from 2022 peaks, BMI 2024).

Electra Battery Materials Posts GAAP EPS of -C$4.16: Electra reported GAAP EPS of -C$4.16 on Mar 30, 2026 (Source: Seeking Alpha). This large loss heightens liquidity and execution scrutiny… 👈 Read full analysis #ElectraBatteryMaterials #GAAPEPS #BatteryMaterials #MarketInsights #FinancialAnalysis

Athira Pharma Posts GAAP EPS of -$24.70 Athira Pharma reported GAAP EPS of -$24.70 on Mar 27, 2026; investors should await the 10-Q to parse non-cash items, cash runway and financing needs.

Athira Pharma Posts GAAP EPS of -$24.70: Athira Pharma reported GAAP EPS of -$24.70 on Mar 27, 2026; investors should await the 10-Q to parse non-cash items, cash runway and financing needs. 👈 Read full analysis #AthiraPharma #GAAPEPS #Investing #FinanceNews #StockMarket

Medicus Pharma Reports GAAP EPS $2.74 Medicus Pharma reported GAAP EPS of $2.74 on Mar 26, 2026 (Seeking Alpha); investors should await the 8-K/10-Q for reconciliations and details on recurring revenue.

Medicus Pharma Reports GAAP EPS $2.74: Medicus Pharma reported GAAP EPS of $2.74 on Mar 26, 2026 (Seeking Alpha); investors should await the 8-K/10-Q for reconciliations and details on recurring revenue. 👈 Read full analysis #MedicusPharma #GAAPEPS #Investing #FinanceNews #StockMarket

Innate Pharma Posts GAAP EPS -€0.55, Revenue €9.01M Innate Pharma reported GAAP EPS of -€0.55 and revenue €9.01M on Mar 26, 2026 (Seeking Alpha). Immediate focus: cash runway, milestone timing, and clinical catalysts.

Innate Pharma Posts GAAP EPS -€0.55, Revenue €9.01M: Innate Pharma reported GAAP EPS of -€0.55 and revenue €9.01M on Mar 26, 2026 (Seeking Alpha). Immediate focus: cash runway, milestone timing, and… 👈 Read full analysis #InnatePharma #GAAPEPS #RevenueReport #ClinicalTrials #FinancialAnalysis

Cheer Holding Reports GAAP EPS $24.07, Revenue $148.8M Cheer Holding posted GAAP EPS $24.07 and $148.8M revenue on Mar 23, 2026, prompting immediate scrutiny of whether earnings are recurring or driven by one-offs.

Cheer Holding Reports GAAP EPS $24.07, Revenue $148.8M: Cheer Holding posted GAAP EPS $24.07 and $148.8M revenue on Mar 23, 2026, prompting immediate scrutiny of whether earnings are recurring or driven by… 👈 Read full analysis #CheerHolding #GAAPEPS #EarningsReport #RevenueGrowth #FinancialAnalysis

Avalo Therapeutics Q4 GAAP EPS -$5.84 Beats Estimates Avalo posted GAAP EPS of -$5.84 (beat by $0.47) and revenue $0.06M on Mar 23, 2026; cash runway and upcoming readouts remain decisive for valuation.

Avalo Therapeutics Q4 GAAP EPS -$5.84 Beats Estimates: Avalo posted GAAP EPS of -$5.84 (beat by $0.47) and revenue $0.06M on Mar 23, 2026; cash runway and upcoming readouts remain decisive for… 👈 Read full analysis #AvaloTherapeutics #EarningsReport #GAAPEPS #FinancialResults #InvestmentInsights

Vertex Resource Posts C$54.83M Revenue, GAAP EPS -C$0.06 Vertex Resource reported C$54.83M revenue and GAAP EPS of -C$0.06 on Mar 23, 2026; follow‑up on adjusted EBITDA, cash flow and backlog is essential.

Vertex Resource Posts C$54.83M Revenue, GAAP EPS -C$0.06: Vertex Resource reported C$54.83M revenue and GAAP EPS of -C$0.06 on Mar 23, 2026; follow‑up on adjusted EBITDA, cash flow and backlog is essential. 👈 Read full analysis #VertexResource #EarningsReport #Revenue #GAAPEPS #FinancialNews